guidanc wors expect may reignit
concern health market and/or share
convinc busi fundament
soften materi sinc novemb clear
underli market slow pt
guidanc focu result line
pre-announce debat center guidanc expect
low guidanc vs mse con
still came expect key question delv
whether expect growth year flat us y/i
growth suggest deterior senza market
factor influenc us market growth analysi suggest annual
growth rang correspond declin ex-u flat constant currenc
us growth low end us market growth outlook
provid follow remind similar msd
growth seen market launch catalyz growth
doubl digit recent abbott growth slow markedli
latest result see deriv commentari point
slowdown market model suggest growth slow
pt momentum deceler price/mix new system launch
replac cycl dynam inventori impact perceiv
market growth like larger factor recent deceler
guidanc mean us guidanc impli growth
line market bp us share loss assum
market model estim growth accur sharper deceler
us like rais concern market growth address
limit share captur whether guidanc concern
conserv matter perspect import note line
manag saw us market novemb
chang two month guidanc flat us y/i perform soft
given deep quarter may conserv
import note consist histor season annual
revenu q/q dollar declin seen last two year
convinc continu deceler reflect new pressur rather
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
continu competit pressur sale rep disrupt seen throughout
ad understood headwind australia reimburs
pressur discuss soften market said channel
dilig warrant better understand slowdown de novo implant
trend confirm physician check last even
australia expect headwind referenc follow nan
thought australia underappreci headwind given chang
reimburs dynam creat less visibl environ
implement april estim australia ou
busi could drive pt bp headwind ou
ww growth respect remain ou busi could grow hsd
reimburs challeng anniversari
word spend oper expens expect
exclud litig expens y/i increas follow increas
impli neg leverag busi primarili driven dtc
market invest nation account increas rep hire toward end
desir spend channel pipelin develop
neg revenu cycl decis support
matter next catalyst path year greater
visibl come quarter end market trend share
key catalyst commerci traction enthusiasm senza new multi-
modal platform launch late enthusiasm around
indic expans pain diabet neuropathi senza-pdn non-
surgic back senza-nsrbp approach data readout think
question market growth take time play acknowledg
could look brighter investor enthusiasm around
stori increas price target move reflect sale
switch multiple-bas methodolog smid cap comp group exhibit
current trade sale median growth rate
think modestli lower growth question market recent execut
issu warrant discount extent get visibl item
higher multipl may warrant interim rel underweight
rate base view less senza differenti recent execut
issu drive growth deceler midst catalyst void
price target reflect ev/sal discount versu
smid cap med-tech given modestli lower growth question
market recent execut issu
share gain expans market growth stay low mid-teen
net share gainer addit make substanti
progress expans opportun
differenti slower market growth weigh share revenu growth
lose us share
competit respons creat headwind progress date low-hang
fruit futur uptak prove challeng market prove
sensit market clinic data materi lose share
market slow lead multipl contract
rel underweight rate base
view less senza differenti
recent execut issu drive growth
deceler midst catalyst void
question market deceler
year could weigh share
clinic data expand
key data pain diabet neuropathi
non-surg back come
suggest clinic catalyst void
interim
channel check suggest senza
differenti practic data suggest
pt ww share increas
revenu
pt us share increas
revenu
pt us market growth assum
pro rata share increas revenu
competit launch data on-going
risk achiev price
sale rep hire anniversari
competitor product potenti help
pdn senza-nsrbp
million except ep
sale
sale
sale
sale
sale
sale
accret redeem convert prefer stock redempt valu
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
accumul comprehens loss
dollar million except per share data
non-cash loss extinguish debt
payment origin issu discount
provis doubt account
write-down inventori
unreal loss foreign currenc transact
purchas short-term invest
proce matur short-term invest
chang restrict cash
proce issuanc common stock underwritten public offer
proce issuanc convert note
convert note initi issuanc discount debt issuanc cost
proce issuanc warrant
purchas convert note hedg
repay debt
purchas common stock proce issuanc common stock stock option exercis
begin period
end period
million
